7th SYMPOSIUM ON THE NEUROVIROLOGY AND NEUROIMMUNOLOGY OF SCHIZOPHRENIA AND BIPOLAR DISORDER

7th SYMPOSIUM ON THE NEUROVIROLOGY

AND NEUROIMMUNOLOGY OF SCHIZOPHRENIA AND BIPOLAR DISORDER

FOCUS ON GENOMICS, PROTEOMICS, AND

CLINICAL TRIALS

AGENDA

Genomics and Proteomics

INTRODUCTION

TO THE STANLEY BRAIN COLLECTION

E. Fuller Torrey and Maree Webster, Stanley Medical Research Institute

CHARACTERISTICS

OF RNA THAT AFFECT cDNA GENERATION AND ARRAY HYBRIDIZATION

Christine L. Miller and Robert H. Yolken, Stanley Division of Developmental

Neurovirology, Johns Hopkins University

STATISTICAL

ANALYSES OF GENOMIC AND PROTEOMIC MEASUREMENTS IN HUMAN POSTMORTEM BRAIN TISSUE

Dawn Dhavale, Stanley Medical Research Institute

Genomic Studies of Schizophrenia and

Bipolar Disorder

GENE

EXPRESSION ANALYSIS IN SCHIZOPHRENIA: REPRODUCIBLE UPREGULATION OF SEVERAL

MEMBERS OF THE APOLIPOPROTEIN L FAMILY LOCATED IN A HIGH SUSCEPTIBILITY LOCUS

FOR SCHIZOPHRENIA ON CHROMOSOME 22

Sabine Bahn, Addenbrook’s Hospital, University of Cambridge

MICROARRAY

ANALYSIS OF THE STANLEY BRAIN COLLECTION

Pamela Sklar, Whitehead Institute

PRELIMINARY SCREENING OF GENE

EXPRESSION IN SCHIZOPHRENIA BY cDNA MICROARRAY

Marquis P. Vawter, University of California at Irvine

SCHIZOPHRENIA AS A

DISEASE OF THE SYNAPSE

Karoly Mirnics, University of Pittsburgh

Genomic Studies of Other

Neuropsychiatric Diseases

RNA PROFILING IN NEUROPSYCHIATRIC AND NEURODEGENERATIVE

DISORDERS

Allen Fienberg, Rockefeller University

TECHNOLOGIES

AND STRATEGIES FOR STUDYING GENE EXPRESSION CHANGES IN PSYCHIATRIC DISEASE

C. Anthony Altar, Psychiatric Genomics, Inc., Gaithersburg, MD

ASSEMBLY

OF A NEUROPSYCHIATRIC cDNA ARRAY

Kevin Becker, DNA Array Unit, NIA, NIH, Baltimore, MD

PROFILING

THE BRAIN WITH MICROARRAYS – DATA ANALYSIS ISSUES

Simon Lin, Bioinformatics, Duke University

GENE

EXPRESSION CHANGES FOLLOWING NEONATAL VENTRAL HIPPOCAMPAL LESIONS

Graham K. Wood, McGill University, Montreal PQ, Canada

Proteomic Studies of Schizophrenia

THE

HUMAN BRAIN PROTEOME: INITIAL RESULTS FROM THE HUMAN PROTEIN INDEX™ PROJECT

Leigh Anderson, Large Scale Biology Corporation

PROTEINCHIP

PROTEOMICS FOR PROFILING OF NEUROPSYCHIATRIC DISEASE

Eric Fung, Ciphergen Biosystems, Fremont, CA

Poster Presentations

PRELIMINARY

EXAMINATION OF REGIONAL DISTRIBUTION OF HUMAN CORONAVIRUS RNA IN POST MORTEM

HUMAN BRAIN

Arlene R. Collins, Lynn Diviak, Alicia Arnold and Mary J. Evans, State

University of New York at Buffalo

CLONALLY EXPANDED T CELLS ARE PRESENT

IN THE CSF OF PATIENTS WITH MAJOR DEPRESSION

Emilia Oleszak, Temple University School of

Medicine, Philadelphia, PA

MICROARRAY

STUDIES – AN INTEGRATIVE PLATFORM FOR CASE-CONTROL STUDIES AND ANIMAL MODELS OF

SCHIZOPHRENIA

Francois Feron, Queensland Centre for

Schizophrenia Research, Australia

ALTERED

LEVELS OF REELIN AND ITS ISOFORMS IN SCHIZOPHRENIA AND MOOD DISORDERS

SH Fatemi, University of Minnesota

TGF-BETAL

EXPRESSION IN SUBJECTS WITH MOOD DISORDERS AND LITHIUM-TREATED RATS

Yarema B. Bezchlibnyk, Jun-Fen Wang, Glenda M. MacQueen, L. Trevor Young,

McMasters University

DEVELOPMENT

OF BROADLY AMPLIFYING REAL TIME PCRs FOR DETECTION AND QUANTIFICATION OF

RETROVIRAL NUCLEIC ACID

Jonas Blomberg, Uppsala, Sweden

GENOMIC

DNA STABILITY AND SCHIZOPHRENIA IN TWINS

Cassandra L. Smith, Boston University

RETROVIRAL REACTIVITY OF PERINATAL SERA

FROM MOTHERS WHOSE CHILDREN DEVELOPED SCHIZOPHRENIA

Erik P. Lillehoj, Steve Buka, E. Fuller Torrey, Robert H. Yolken

PRELIMINARY

EVALUATION OF VIRUSES AND INTRACELLULAR BACTERIA STATUS IN URBAN CATS AND THEIR

RELATIONSHIP WITH DEVELOPMENT OF SCHIZOPHRENIA IN HUMAN

Reza Firouzi, Lyons, France

QUALITATIVE

ASSESSMENT OF RETROVIRAL ACTIVITY IN HUMAN BRAIN AND TISSUE

Wolfgang Seifarth, University of Heidelberg, Germany

DETECTION OF A 68 Kd

PROTEIN BY WESTERN IMMUNOBLOT IN SAMPLES REACTIVE TO BARTONELLA HENSELAE

BY AN IMMUNOFLUORESCENT ASSAY

Glen Ford, Roveko, Gaithersburg, MD

IN UTERO EXPOSURE TO INFLUENZA A

VIRUS, TRANSPLACENTAL PASSAGE AND INFLUENCE ON GENE EXPRESSION IN THE FETAL

MOUSE BRAIN

Håkan, Karlsson, Karolinska Institute

DEFICIENT CALCIUM-DEPENDENT NITRIC OXIDE SYNTHASE ACTIVITY IN

THE PREFRONTAL CORTEX OF SCHIZOPHRENIA AND DEPRESSION

Guoqiang Xing, USUHS, Bethesda, Md

Clinical Trials

TRANSLATIONAL

MODELS OF DRUG DEVELOPMENT FOR THE TREATMENT OF SCHIZOPHRENIA

Jeffrey A. Lieberman, University of North Carolina School of Medicine

GENOME-WIDE

EXPRESSION ANALYSIS REVEALS DYSREGULATION OF MYELINATION-RELATED GENES IN

CHRONIC SCHIZOPHRENIA

Kenneth L. Davis, Mt. Sinai School of Medicine

DEVELOPING

MEDICATION STRATEGIES FOR RELAPSE PREVENTION IN SCHIZOPHRENIA

John Kane, Hillside Hospital

THE

FUTURE PSYCHOPHARMACOLOGY OF MOOD AND ANXIETY DISORDER

Dennis S. Charney, NIH

MODULATION

OF NEUROTROPHIC SIGNALING CASCADES BY MOOD STABILIZING AGENTS: PUTATIVE

MEDIATORS OF LONG TERM THERAPEUTIC EFFECTS IN BIPOLAR DISORDER

Husseini K. Manji, National Institute of Mental Health

IN

VIVO BRAIN IMAGING AND DRUG DEVELOPMENT

Clinton Kilts, Emory University School of Medicine, Atlanta, GA

ANTI-INFLAMMATORY

AGENTS FOR SCHIZOPHRENIA

Norbert Müller, Ludwig-Maximilians University

PHARMACOGENOMIC

STRATEGIES FOR NEW DRUG DEVELOPMENT

Anil K. Malhotra, Hillside Hospital, Albert Einstein College of Medicine

ANTIMICROBIAL AGENTS –

POTENTIAL ROLE IN HUMAN PSYCHIATRIC DISEASES

Robert H. Yolken, Stanley Division of Developmental Neurovirology, Johns

Hopkins University

STRATEGIES FOR

SELECTING TARGETS FOR DRUG DEVELOPMENT IN SCHIZOPHRENIA

Carol A. Tamminga, University of Maryland School of Medicine

REELIN, GAD 67, AND

PSYCHOSIS

John M. Davis, University of Illinois at Chicago

COMPENSATORY

PROCESSES MAINTAINING FUNCTION AFTER GENE DELETION OF DA RECEPTOR SUBTYPES

INDICATE NOVEL DRUG TARGETS

John L. Waddington, Royal College of Surgeons in Ireland